Showing 15 posts of 38 posts found.


AstraZeneca’s Alexion partners with Pfizer for rare disease therapies

July 28, 2023
Research and Development Alexion, AstraZeneca, Pfizer, Rare Diseases, genomics, rare disease

Alexion, AstraZeneca’s Rare Disease division, has announced that it has entered a definitive purchase and licence agreement with Pfizer. The …


Alexion pauses Phase III ULTOMIRIS COVID-19 trial enrolment

January 15, 2021
Medical Communications Alexion, COVID-19

Alexion has paused further enrolment in the global Phase III study of ULTOMIRIS (ravulizumab-cwvz) in adult COVID-19 patients requiring mechanical …


AstraZeneca to buy Alexion in $39 billion deal

December 14, 2020
Sales and Marketing Alexion, AstraZeneca, merger

British-Swedish AstraZeneca is set to acquire American biopharmaceutical company Alexion for $39 billion, in a move that will see a …


Alexion’s Ondexxya approved for NHS Scotland to treat uncontrolled and life-threatening bleeds

September 9, 2020
Research and Development, Sales and Marketing Alexion, NHS, Ondexxya, Scotland, nhs scotland

The Scottish Medicines Consortium (SMC) has given its recommendation to Alexion’s Ondexxya (andexanet alfa) to routine use on NHS Scotland …


Portola Pharmaceuticals to merge with Alexion in $1.41bn cash deal

May 6, 2020
Research and Development, Sales and Marketing Alexion, Portola Pharmaceuticals, pharma

Alexion has announced it is to acquire Boston-based blood disorder specialist Portola Pharmaceuticals in a transaction to the value of …


Apellis therapy outflanks Alexion’s Soliris in head-to-head paroxysmal nocturnal haemoglobinuria

January 8, 2020
Research and Development Alexion, Appelis, pegcetacoplan, pharma, soliris

Apellis Pharmaceuticals has revealed new Phase 3 demonstrating that its targeted C3 inhibitor pegcetacoplan met its primary endpoint and outclassed …


FDA approves Alexion’s Ultomiris in atypical haemolytic uremic syndrome for adults and children

October 21, 2019
Sales and Marketing Alexion, FDA, Ultomiris, pharma, rare disease

The FDA has moved to expand the existing label for Alexion’s Ultomiris (ravulizumab-cwvz) to include the treatment of atypical haemolytic …


Alexion to acquire Achillion Pharma for $930 million

October 16, 2019
Research and Development, Sales and Marketing Alexion, achillion, merger, pharma

Alexion has revealed it has signed a definitive agreement to acquire Achillion Pharmaceuticals in a deal valued at $930 million, …


Alexion’s Soliris scoops up expanded EU approval in neuromyelitis optica spectrum disorder

August 28, 2019
Research and Development, Sales and Marketing Alexion, FDA, US, pharma, soliris

Alexion has announced the expanded EU approval of Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder (NMOSD) in …


European approval for Alexion’s Ultomiris in rare blood disease

July 4, 2019
Sales and Marketing Alexion, Europe, Ultomiris, paroxysmal nocturnal haemoglobinuria

Alexion has received marketing authorisation from the European Commission for its long-acting C5 complement inhibitor Ultomiris (ravulizumab) in the treatment …


Alexion’s Soliris almost entirely eliminates relapses in rare neuromyelitis optica spectrum disorder

September 26, 2018
Research and Development Alexion, neuromyelitis optica spectrum disorder, pharma, rare disease, soliris

Alexion has revealed new Phase 3 findings for Soliris (eculizumab), showing the drug met its primary endpoint in the treatment …


Alexion goes back to roots with Complement deal

June 11, 2018
Manufacturing and Production, Sales and Marketing Alexion, biotech, drugs, pharma, pharmaceutical, soliris

Alexion has made a lot of money from investing in the science behind complement inhibitors – C5 inhibitor, Soliris, has …


Investigational Alexion drug proves non-inferior to Soliris in rare blood disease

April 27, 2018
Medical Communications, Research and Development Alexion, paroxysmal nocturnal haemoglobinuria, pharma, soliris

Alexion has lifted the curtain on new data for its C5 complement inhibitor ALXN1210, demonstrating its non-inferiority to another of …

Alexion $855m portfolio boost after Wilson Therapeutics buyout

April 11, 2018
Research and Development, Sales and Marketing Alexion, Wilson's Therapeutics, Wilson's disease, biotech, drugs, pharma, pharmaceutical

Alexion Pharmaceuticals is badly in need of alternative revenue streams to Soliris, its mega-blockbuster that could start to face competition …

Alexion moves to bolster patent protection of Soliris

August 17, 2017
Sales and Marketing Alexion, biotech, drugs, pharma, pharmaceutical, soliris

Soliris brought in net sales of $2.8 billion last year for Alexion, meaning it accounted for close to 90% of …

Latest content